J&J to acquire Proteologix for US$850 million
Add BT as a preferred source
JOHNSON & Johnson said on Thursday (May 16) it would acquire Proteologix for US$850 million in cash, as it looks to gain access to the privately held company’s experimental atopic dermatitis treatments.
Proteologix’s antibody PX128 is ready to enter early-stage development for moderate to severe atopic dermatitis, commonly referred to as eczema, and moderate to severe asthma. PX130, its other antibody, is in preclinical development for moderate to severe atopic dermatitis.
Atopic dermatitis is a chronic inflammatory skin disorder that causes damage to the skin barrier, leaving it dry, itchy, and prone to skin infections.
J&J’s experimental atopic dermatitis drug is in mid-stage development, according to its website.
The transaction is expected to close in the next few months, subject to antitrust clearance and other customary closing conditions.
The deal also has potential for an additional milestone payment, J&J said. REUTERS
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Share with us your feedback on BT's products and services
TRENDING NOW
CSE Global independent director quits after clashes with chairman Eugene Lai over board refresh
‘I felt like dying’: Thai Singha beer scion speaks up after disclosure of alleged sexual abuse
Cat A COE rate exceeds Cat B for third time in 4 months; premiums largely down
What’s wrong with Orchard Road? Experts weigh in on the street’s cachet and its future
